Amebocyte Lysate Market By Type (Limulus Amebocyte Lysate, Tachypleus Amebocyte Lysate) , By Application (Drug Testing, Clinical Diagnosis, Other) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Description

Amebocyte Lysate Market

The amebocyte lysate market was valued at $0.6 billion in 2023 and is projected to reach $1.9 billion by 2033, growing at a CAGR of 11.8% from 2024 to 2033.

Amebocyte lysate, derived from the blood cells or amebocytes of horseshoe crabs, is well-known for its unique property of clotting in the presence of bacterial endotoxins. It is a crucial component in the field of biomedical research & pharmaceuticals and is particularly utilized for the detection of bacterial endotoxins. Due to its exceptional sensitivity, amebocyte lysate is used in environmental monitoring, particularly for the assessment of quality of water and other environmental samples for bacterial contamination.

The field of drug testing is a significant driver of the amebocyte lysate market. Several stages of drug testing such as raw material testing, in-process testing, and final product testing make use of amebocyte lysate and limulus amebocyte lysate (LAL) test for pharmaceutical development. In recent times, recombinant DNA technology is trending for the utilization of properties of amebocyte lysate in different applications. Ther technology develops copies of the genetic components of amebocyte lysate and offers benefits such as scalability, consistency, & reduced reliance on horseshoe crab populations.

However, compliance with the pharmacopeial regulations established in different countries is a complex and expensive challenge for the market players which prevents the growth of the market. In addition, the ethical considerations regarding the usage of animals in testing and the sustainability of natural resources used in amebocyte lysate production hinder market development. To combat such issues, AmeboGenesis(TM), a research and discovery organization, introduced a sustainable way of production of amebocytes. This is an innovative method which utilizes a sustainable approach involving the reaping of leg muscles of a horseshoe crab, culturing, and differentiating them into amebocytes by the use of totipotent stem cells. This process ensures a significant control over amebocyte production, along with consistent LAL concentration & production. This approach prevents the annual harvest and bleeding of approximately 800,000 horseshoe crabs, with a notably low survival rate post-harvesting.

Segment Review

The amebocyte lysate market is segmented into type, application, and region. By type, the market is bifurcated into limulus amebocyte lysate and tachypleus amebocyte lysate. On the basis of application, it is divided into drug testing, clinical diagnosis, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the limulus amebocyte lysate segment was the major shareholder in 2023.

Depending on application, the drug testing segment garnered a major share in 2023.

The amebocyte lysate market is expected to experience rapid growth In Asia Pacific by 2033.

Competition Analysis

The major players operating in the global amebocyte lysate market include Lonza Group AG, Charles River Laboratories, Associates Of Cape Cod, Xiamen Bioendo Technology, Zhanjiang A&c Biological, GenScript, Nelson Laboratories, LLC, Thermo Fisher Scientific, Inc., Merck & Co, and Microcoat Biotechnologie GmbH. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

Limulus Amebocyte Lysate
Tachypleus Amebocyte Lysate

By Application

Drug Testing
Clinical Diagnosis
Other

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Lonza Group AG
Charles River Laboratories
Associates of Cape Cod Inc
Xiamen Bioendo Technology
Zhanjiang A&C Biological
Genscript Technology Corporation
Nelson Laboratories, LLC
Thermo Fisher Scientific, Inc.
Merck & Co., Inc.
Microcoat Biotechnologie GmbH

Product Code: A65445

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope
3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: AMEBOCYTE LYSATE MARKET, BY TYPE

4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Type
4.2. Limulus Amebocyte Lysate
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
4.3. Tachypleus Amebocyte Lysate
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country

CHAPTER 5: AMEBOCYTE LYSATE MARKET, BY APPLICATION

5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Application
5.2. Drug Testing
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
5.3. Clinical Diagnosis
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
5.4. Other
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country

CHAPTER 6: AMEBOCYTE LYSATE MARKET, BY REGION

6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Region
6.2. North America
- 6.2.1. Key Market Trends and Opportunities
- 6.2.2. Market Size and Forecast, By Type
- 6.2.3. Market Size and Forecast, By Application
- 6.2.4. Market Size and Forecast, By Country
- 6.2.5. U.S. Amebocyte Lysate Market
  - 6.2.5.1. Market Size and Forecast, By Type
  - 6.2.5.2. Market Size and Forecast, By Application
- 6.2.6. Canada Amebocyte Lysate Market
  - 6.2.6.1. Market Size and Forecast, By Type
  - 6.2.6.2. Market Size and Forecast, By Application
- 6.2.7. Mexico Amebocyte Lysate Market
  - 6.2.7.1. Market Size and Forecast, By Type
  - 6.2.7.2. Market Size and Forecast, By Application
6.3. Europe
- 6.3.1. Key Market Trends and Opportunities
- 6.3.2. Market Size and Forecast, By Type
- 6.3.3. Market Size and Forecast, By Application
- 6.3.4. Market Size and Forecast, By Country
- 6.3.5. Germany Amebocyte Lysate Market
  - 6.3.5.1. Market Size and Forecast, By Type
  - 6.3.5.2. Market Size and Forecast, By Application
- 6.3.6. France Amebocyte Lysate Market
  - 6.3.6.1. Market Size and Forecast, By Type
  - 6.3.6.2. Market Size and Forecast, By Application
- 6.3.7. UK Amebocyte Lysate Market
  - 6.3.7.1. Market Size and Forecast, By Type
  - 6.3.7.2. Market Size and Forecast, By Application
- 6.3.8. Italy Amebocyte Lysate Market
  - 6.3.8.1. Market Size and Forecast, By Type
  - 6.3.8.2. Market Size and Forecast, By Application
- 6.3.9. Spain Amebocyte Lysate Market
  - 6.3.9.1. Market Size and Forecast, By Type
  - 6.3.9.2. Market Size and Forecast, By Application
- 6.3.10. Rest of Europe Amebocyte Lysate Market
  - 6.3.10.1. Market Size and Forecast, By Type
  - 6.3.10.2. Market Size and Forecast, By Application
6.4. Asia-Pacific
- 6.4.1. Key Market Trends and Opportunities
- 6.4.2. Market Size and Forecast, By Type
- 6.4.3. Market Size and Forecast, By Application
- 6.4.4. Market Size and Forecast, By Country
- 6.4.5. Japan Amebocyte Lysate Market
  - 6.4.5.1. Market Size and Forecast, By Type
  - 6.4.5.2. Market Size and Forecast, By Application
- 6.4.6. China Amebocyte Lysate Market
  - 6.4.6.1. Market Size and Forecast, By Type
  - 6.4.6.2. Market Size and Forecast, By Application
- 6.4.7. Australia Amebocyte Lysate Market
  - 6.4.7.1. Market Size and Forecast, By Type
  - 6.4.7.2. Market Size and Forecast, By Application
- 6.4.8. India Amebocyte Lysate Market
  - 6.4.8.1. Market Size and Forecast, By Type
  - 6.4.8.2. Market Size and Forecast, By Application
- 6.4.9. South Korea Amebocyte Lysate Market
  - 6.4.9.1. Market Size and Forecast, By Type
  - 6.4.9.2. Market Size and Forecast, By Application
- 6.4.10. Rest of Asia-Pacific Amebocyte Lysate Market
  - 6.4.10.1. Market Size and Forecast, By Type
  - 6.4.10.2. Market Size and Forecast, By Application
6.5. LAMEA
- 6.5.1. Key Market Trends and Opportunities
- 6.5.2. Market Size and Forecast, By Type
- 6.5.3. Market Size and Forecast, By Application
- 6.5.4. Market Size and Forecast, By Country
- 6.5.5. Brazil Amebocyte Lysate Market
  - 6.5.5.1. Market Size and Forecast, By Type
  - 6.5.5.2. Market Size and Forecast, By Application
- 6.5.6. Saudi Arabia Amebocyte Lysate Market
  - 6.5.6.1. Market Size and Forecast, By Type
  - 6.5.6.2. Market Size and Forecast, By Application
- 6.5.7. South Africa Amebocyte Lysate Market
  - 6.5.7.1. Market Size and Forecast, By Type
  - 6.5.7.2. Market Size and Forecast, By Application
- 6.5.8. Rest of LAMEA Amebocyte Lysate Market
  - 6.5.8.1. Market Size and Forecast, By Type
  - 6.5.8.2. Market Size and Forecast, By Application

CHAPTER 7: COMPETITIVE LANDSCAPE

7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

8.1. Lonza Group AG
- 8.1.1. Company Overview
- 8.1.2. Key Executives
- 8.1.3. Company Snapshot
- 8.1.4. Operating Business Segments
- 8.1.5. Product Portfolio
- 8.1.6. Business Performance
- 8.1.7. Key Strategic Moves and Developments
8.2. Charles River Laboratories
- 8.2.1. Company Overview
- 8.2.2. Key Executives
- 8.2.3. Company Snapshot
- 8.2.4. Operating Business Segments
- 8.2.5. Product Portfolio
- 8.2.6. Business Performance
- 8.2.7. Key Strategic Moves and Developments
8.3. Associates of Cape Cod Inc
- 8.3.1. Company Overview
- 8.3.2. Key Executives
- 8.3.3. Company Snapshot
- 8.3.4. Operating Business Segments
- 8.3.5. Product Portfolio
- 8.3.6. Business Performance
- 8.3.7. Key Strategic Moves and Developments
8.4. Xiamen Bioendo Technology
- 8.4.1. Company Overview
- 8.4.2. Key Executives
- 8.4.3. Company Snapshot
- 8.4.4. Operating Business Segments
- 8.4.5. Product Portfolio
- 8.4.6. Business Performance
- 8.4.7. Key Strategic Moves and Developments
8.5. Zhanjiang A&C Biological
- 8.5.1. Company Overview
- 8.5.2. Key Executives
- 8.5.3. Company Snapshot
- 8.5.4. Operating Business Segments
- 8.5.5. Product Portfolio
- 8.5.6. Business Performance
- 8.5.7. Key Strategic Moves and Developments
8.6. Genscript Technology Corporation
- 8.6.1. Company Overview
- 8.6.2. Key Executives
- 8.6.3. Company Snapshot
- 8.6.4. Operating Business Segments
- 8.6.5. Product Portfolio
- 8.6.6. Business Performance
- 8.6.7. Key Strategic Moves and Developments
8.7. Nelson Laboratories, LLC
- 8.7.1. Company Overview
- 8.7.2. Key Executives
- 8.7.3. Company Snapshot
- 8.7.4. Operating Business Segments
- 8.7.5. Product Portfolio
- 8.7.6. Business Performance
- 8.7.7. Key Strategic Moves and Developments
8.8. Thermo Fisher Scientific, Inc.
- 8.8.1. Company Overview
- 8.8.2. Key Executives
- 8.8.3. Company Snapshot
- 8.8.4. Operating Business Segments
- 8.8.5. Product Portfolio
- 8.8.6. Business Performance
- 8.8.7. Key Strategic Moves and Developments
8.9. Merck And Co., Inc.
- 8.9.1. Company Overview
- 8.9.2. Key Executives
- 8.9.3. Company Snapshot
- 8.9.4. Operating Business Segments
- 8.9.5. Product Portfolio
- 8.9.6. Business Performance
- 8.9.7. Key Strategic Moves and Developments
8.10. Microcoat Biotechnologie GmbH
- 8.10.1. Company Overview
- 8.10.2. Key Executives
- 8.10.3. Company Snapshot
- 8.10.4. Operating Business Segments
- 8.10.5. Product Portfolio
- 8.10.6. Business Performance
- 8.10.7. Key Strategic Moves and Developments